Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1, Single Ascending Dose Study of Subcutaneous BW-50218 in Healthy Participants
NCT07401472Phase 1Active, not recruiting
- Sponsor
- Shanghai Argo Biopharmaceutical Co., Ltd.
- Start
- Mar 2026
- Primary completion
- Jun 2027
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BW-50218 in transthyretin amyloidosis (ATTR) (7 arms), sponsored by Shanghai Argo Biopharmaceutical Co., Ltd. Primary endpoints: Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) at Day 360, Change from Baseline in Clinical Laboratory Test Results at Day 360 and 3 more. Started Mar 2026; status: active, not recruiting.
02
Drugs
BW-50218
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT07401472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07401472.